Hints and tips:
...Speed was crucial, so Pfizer had to change how it worked....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...The company’s pipeline had been transformed since the Parisian saw off a takeover bid from Pfizer in 2014....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If a takeover of Shire is consummated at current valuations, it would rank as one of the largest the pharmaceutical sector has ever seen, trailing Pfizer’s $112bn takeover of Warner Lambert in 2000, data...
...Together, these and a series of other deals have created the most vigorous period of mergers and acquisitions among drugmakers since the turn of the century, when Pfizer bought Warner-Lambert and Glaxo Wellcome...
...He initially showed little interest in megamergers of the kind Pfizer carried out in the prior decade with Wyeth and Warner-Lambert....
...Bizarrely, this round of mergers is supposed to solve the problems created by the last one — the burst of activity in which large pharmaceuticals groups such as GlaxoSmithKline and Pfizer, which bought Warner-Lambert...
...That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth....
...bought by Pfizer....
...Megamergers such as Pfizer’s $90bn takeover of Warner-Lambert in 1999 and SmithKline’s $72bn merger with Glaxo had struggled to produce growth....
...Fan club Sir Richard Lambert, author of the Banking Standards Review, is long on alliteration, writes Kate Burgess....
...Pfizer’s bid for Warner Lambert was for a product already on the market. This time it’s about access to the R&D pipeline.”...
...He said the commitments offered by Pfizer “fly in the face of what they have done when they have acquired companies in the past”, pointing to job losses after takeovers of Pharmacia and Warner Lambert....
...For Pfizer, a deal would add to its history of megamergers, including its $69bn takeover of Wyeth in 2009 and its $111.8bn deal with Warner-Lambert in 2000....
...This would make it the biggest pharma deal since Pfizer’s $111.8bn takeover of Warner-Lambert in 2000....
...The $112bn acquisition of Warner-Lambert in 2000 provided access to Lipitor, the cholesterol treatment which, in the hands of Pfizer’s salesmen, became the world’s first $10bn-a-year drug....
...“There is its acquisition of Warner-Lambert in 2000 in the US; Pharmacia in Sweden in 2003; and Wyeth in the US in 2000, and that led to deep cuts in the research facilities, it led to intellectual asset-stripping...
...Rezulin was withdrawn in 2000 by Warner-Lambert (now part of Pfizer) because of liver toxicity....
...Since 2000, the company has spent more than $200bn on the acquisition of Warner-Lambert, Pharmacia and Wyeth. Yet, the deals have done little to improve the underlying trend....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...You cannot have a website where you have MasterPass, V.me, Google Wallet, iTunes and several others.”...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
International Edition